ClinicalTrials.gg

Program

gepotidacin

Also written as “Gepotidacin”, “GSK2140944” and “Gepotidacin Capsule”.

Its studies are mostly in Bacterial Infections · Urinary Tract Infections · Respiratory Tract Infections · Gonorrhea, led by GlaxoSmithKline.

Furthest: phase 3, since Jul 2, 201923 company-led studies, 2 open or runningNext primary completion: May 17, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
GlaxoSmithKline232 open or runningphase 3since Jul 2, 2019Mar 29, 2012May 17, 2027phase 1 · NCT07645235

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 8 studies since Mar 29, 2012.

  1. Nov 17, 2014Phase 2 study in GonorrheaNCT02294682 · 106 enrolled · United States, Puerto Rico, United Kingdom
  2. Mar 31, 2016Phase 1 study in Bacterial InfectionsNCT02729038 · 32 enrolled · United States
  3. Jul 29, 2016Phase 1 study in Bacterial InfectionsNCT02853435 · 48 enrolled · United States
  4. May 15, 2018Phase 1 study in Bacterial InfectionsNCT03562117 · 25 enrolled · United States
  5. Jun 11, 2018Phase 2 study in Bacterial InfectionsNCT03568942 · 22 enrolled · United States
  6. Jul 2, 20192 phase 3 studiesNCT04010539, NCT04020341
  7. Sep 3, 2019Phase 1 study in Bacterial InfectionsNCT04079790 · 34 enrolled · United States
  8. Dec 3, 2019Phase 3 study in Urinary Tract InfectionsNCT04187144 · 1,606 enrolled · United States, Australia, Bulgaria and more
  9. Jul 28, 2020Phase 1 study in Bacterial InfectionsNCT04493931 · 64 enrolled · United States
  10. Feb 28, 2022Phase 1 study in Healthy VolunteersNCT05271799 · 24 enrolled · United States
  11. Nov 23, 2022Phase 3 study in Urinary Tract InfectionsNCT05630833 · 380 enrolled · Japan
  12. Sep 3, 2024Phase 3 study in Urinary Tract InfectionsNCT06597344 · 97 enrolled · United States
  13. Jan 19, 2026Phase 1 study in Urinary Tract InfectionsNCT07371429 · 25 planned · United States
  14. Jun 8, 2026Phase 1 study in Urinary Tract InfectionsNCT07645235 · 8 planned · United States

Ahead

  1. May 17, 2027Primary completion: phase 1 study in Urinary Tract InfectionsNCT07645235
  2. Aug 23, 2027Primary completion: phase 1 study in Urinary Tract InfectionsNCT07371429

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

“Topoisomerase IV inhibitor; Bacterial DNA gyrase inhibitor”ChEMBL 37, by rule

Studies

All 23 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07645235Urinary Tract Infections · United States1RecruitingMay 17, 20278
NCT07371429Urinary Tract Infections · United States1Not yet recruitingAug 23, 202725
NCT06597344Urinary Tract Infections · United States3CompletedMar 10, 202597
NCT05630833Urinary Tract Infections · Japan3CompletedFeb 2, 2024380
NCT05271799Healthy Volunteers · United States1CompletedApr 22, 202224
NCT04493931Bacterial Infections · United States1CompletedDec 21, 202064
NCT04187144Urinary Tract Infections · United States, Australia, Bulgaria and more3CompletedDec 1, 20221,606
NCT04079790Bacterial Infections · United States1CompletedNov 25, 201934
NCT04020341Urinary Tract Infections · United States, Bulgaria, Czechia and more3CompletedNov 30, 20221,531
NCT04010539Gonorrhea · United States, Australia, Germany and more3CompletedOct 10, 2023628
NCT03568942Bacterial Infections · United States2CompletedJan 7, 201922
NCT03562117Bacterial Infections · United States1CompletedDec 26, 201825
NCT02853435Bacterial Infections · United States1CompletedOct 17, 201748
NCT02729038Bacterial Infections · United States1CompletedJun 20, 201732
NCT02294682Gonorrhea · United States, Puerto Rico, United Kingdom2CompletedJul 1, 2016106
NCT02257398Respiratory Tract Infections · United States1CompletedMar 2, 201555
NCT02045849Bacterial Infections · United States1CompletedAug 21, 201446
NCT02045797Bacterial Infections · United States2CompletedJun 29, 2015126
NCT02000765Respiratory Tract Infections · United Kingdom1CompletedNov 30, 20136
NCT01934205Bacterial Infections · United States1CompletedDec 21, 201322
NCT01706315Respiratory Tract Infections · United States1CompletedDec 13, 201372
NCT01615796Respiratory Tract Infections · Australia1CompletedFeb 21, 201486
NCT02202187Respiratory Tract Infections · United States1CompletedFeb 15, 201248

How it is read

Names in the registry

  • “Gepotidacin”, 13 entries
  • “GSK2140944”, 4 entries
  • “Gepotidacin Capsule”, 1 entry
  • “GSK2140944 Lyophile”, 1 entry
  • “GSK2140944 Capsules”, 1 entry

Codes read as this program: GSK2140944.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.